Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 3/20 | 0.46 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14109596 | 0.94 | CA2 (0.60) | CA2CA4SLC22A16CA1CTSL | |
| SCHEMBL11112756 | 0.94 | CA2 (0.60) | CA2CA4SLC22A16CA1CTSL | |
| Silver SCHEMBL6738236 | 0.94 | CA2 (0.60) | CA2CA4SLC22A16CA1CTSL | |
| SCHEMBL10902049 | 0.94 | CA2 (0.68) | CA2CA4SLC22A16CA1CTSL | |
| SCHEMBL11112367 | 0.94 | CA2 (0.60) | CA2CA4SLC22A16CA1CTSL | |
| SCHEMBL6739831 | 0.94 | CA2 (0.60) | CA2CA4SLC22A16CA1CTSL | |
| SCHEMBL14698415 | 0.80 | — | — | |
| Lithium Ion SCHEMBL11691728 | 0.80 | — | — | |
| SCHEMBL28577685 | 0.80 | — | — | |
| SCHEMBL27687073 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501445-B2 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-03-10 | — | — | US | disclosed |
| US-20070049623-A1 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES, A TAIWAN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-7129359-B2 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-10-31 | — | — | US | disclosed |
| US-20040116476-A1 | for treating infection by enterovirus of the Picornaviridae family ; exemplified by: 1-[2-(4'-Chloro-biphenyl-4-yloxymethyl)-benzyl]-3-pyridin-4-yl-imidazolidin-2-one | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049623-A1 | Imidazolidinone compounds | PKN2, PKN1, EIF2AK2 | CA2 2970/4885CA4 2320/4885SLC22A16 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.